This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Stocks Fall Most in Two Years Amidst Debt Ceiling Fears

IBB Chart IBB data by YCharts

BOSTON ( TheStreet) -- Biotech stocks sold off the most in two years Tuesday amidst growing investor concerns that the U.S. government shutdown and looming debt ceiling clash are far from resolved.

The iShares Nasdaq Biotechnology (IBB), the ETF tracking the biotech sector, fell 4.35% to $198.75 Tuesday, far outpacing the 1.23% loss in the S&P 500. The last time the IBB dropped this much in a single day was Oct. 3, 2011, when it lost 4.5%.

Going into today, the IBB was up 52%, so investors appeared to be locking in profits from winning drug and biotech stocks, perhaps in anticipation of a broader market sell off due to the fiscal gridlock in Washington D.C.

There has been much debate recently about whether the surging biotech stock valuations was causing a bubble. That debate will only intensify following today's significant. It remains to be seen if Tuesday's downturn is the start of a major valuation correction in biotech or just a pause in buying that will continue through year's end.

Acadia Pharmaceuticals (ACAD - Get Report) and Insys Therapeutics (INSY - Get Report) -- two of biopharma's best-performing stocks in 2013 -- were among the stocks getting hit the most on Tuesday. Acadia lost 15% to $23.30 while Insys fell 15% to $41.63.

Other double-digits losers today included Geron (GERN - Get Report) (-13%), Prosensa (RNA) (-11%) and Idenix Pharmaceuticals (IDIX) (-16%.)

Among big-cap biotechs, Celgene (CELG - Get Report) lost 3%, Biogen Idec (BIIB) fell 4%, Amgen (AMGN) was down 2% and Gilead Sciences (GILD - Get Report) shed 3.5%.

To put today's biotech selling in further perspective, the IBB has dropped 3% or more in a single day only four times in the past two years. The last occurrence was on Aug. 27. Before that, the IBB lost 3% on Oct. 19, 2012 and June 1, 2012.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ACAD $38.15 -0.21%
CELG $117.45 -2.40%
GERN $2.95 -2.30%
GILD $102.29 -1.50%
INSY $52.17 -6.60%

Markets

DOW 18,154.63 -134.00 -0.73%
S&P 500 2,100.94 -16.45 -0.78%
NASDAQ 4,963.19 -44.9060 -0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs